Brain cancer vaccine shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age from 18 to 75 years (including 18 and 75 years old); 2. Newly-diagnosed glioblastoma confirmed by histopathological exams; 3. IDH1- and IDH2-wild-type gliomas; 4. Extent of resection of enhancing lesions \> 90%; 5. Karnofsky Performance Score(KPS) ≥ 60%; 6. Adequate organ functions: The absolute value of white blood cells ≥ 2.5×10 9/L; Hemoglobin levels\> 100 g/L; Platelet counts \> 100×109/L; Levels of Alanine aminotransferase, aspartate aminotransferase \<2.5 x ULN; Serum creatinine levels \<1.5 x ULN. Exclusion Criteria: 1. Subjects with any other active malignancy; 2. Subjects received the placement of Carmustine implants within 6 months before the inclusion; 3. Subjects with active HBC, HCV or HIV infection; 4. Subjects with grade 2 -3 hypertension or uncontrolled hypertension; 5. Subjects with severe cardio- or cerebro- vascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.; 6. Subjects with uncontrolled autoimmune diseases such as hemolytic anemia, psoriasis and rheumatoid arthritis, etc.; 7. Subjects with severe or uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes; 8. Subjects receiving immunosuppressants after organ transplantation; 9. Within four weeks before the DC vaccinations, subjects receiving systemic administration of steroids with dosage more than 10mg/d prednisone or the equivalent doses of other steroids ( not including inhaled corticosteroid); 10. Subjects with unstable pulmonary embolism, deep venous embolism, or other major arterial and venous thromboembolic events that occur within 30 days before the enrollment; receiving ongoing anticoagulant therapy; 11. Subjects in pregnancy or breastfeeding, or those who plan to become pregnant during treatment or within 2 months after the end of treatment; 12. Within the 14 days before enrollment, subjects with active infections or uncontrolled infections that require systemic antibiotic treatment (except for simple urinary tract infections or upper respiratory tract infections); 13. Subjects who have received other vaccine therapies or gene-modified cell therapy before enrollment; 14. Subjects with number of the predicted neoantigen peptides less than 5; 15. Subjects with other conditions that would interfere trial participation at the investigator's discretion; 16. Subjects with medical conditions that affect signing the written informed consent or complying with the research procedures; or patients who are unwilling or unable to comply with the research procedures; 17. Subjects who participated or are participating in other clinical trials within 4 weeks before enrollment.